The area between the curves gets no respect: Is it because of the median madness? [3]

Journal of Clinical Oncology

Volumn 25, Issue 34, 2007, Pages 5531-

  Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; PLACEBO;

CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; DIGESTIVE SYSTEM CANCER; HUMAN; LETTER; METASTASIS; OUTCOME ASSESSMENT; PANCREAS CANCER; PRIORITY JOURNAL;

CLINICAL TRIALS, PHASE III AS TOPIC; DATA DISPLAY; DATA INTERPRETATION, STATISTICAL; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 36849047718     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.2463     Document Type: Letter

References (7)

1. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 24:4991-4997, 2006
2. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
3. Jonker DJ, Karapetis CS, Moore MJ, et al: Randomized phase III trial of cetuximab monotherapy plus best supportive care versus best supportive care in patients with pretreated metastatic epidermal growth factor receptor positive colorectal carcinoma: A trial of the National Cancer Institute of Canada Clinical Trials Group and the Australian Grastro-Intestinal Trials Group. American Association for Cancer Research Annual Meeting: Proceedings. Apr 14-18, Los Angeles, CA. AACR 2007, Philadelphia, PA (abstr 3535)
4. Philip PA, Benedetti J, Fenoglio-Preiser C, et al: Phase III study of gemcitabine plus cetuximab in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. J Clin Oncol 25:199s, 2007 (abstr 4509)
5. Ilson D: Docetaxel, cisplatin, and fluorouracil in gastric cancer: Does the punishment fit the crime?. J Clin Oncol 25:3188-3190, 2007
6. Kang YK, WS DB, Chen J, et al: Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results. J Clin Oncol 24, 2006 (abstr 4018)
7. Al-Batran SH, Hartmann S, Probst R, et al: A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP). J Clin Oncol 24:182s, 2006 (abstr 4016)